Form 4: Shattuck Labs Director Amy Kate Sasser Granted Stock Options

Shattuck Labs, Inc. director Amy Kate Sasser was granted options to purchase 33,150 shares of common stock with an exercise price of $0.82, vesting over one year.

Summary

• Amy Kate Sasser, a Director of Shattuck Labs, Inc. (STTK), was granted stock options.
• The grant occurred on July 14, 2025, and represents the right to purchase a total of 33,150 shares of the Issuer's common stock.
• The exercise price for these options is $0.82 per share.
• The options will vest in full on the earlier of the one-year anniversary of the grant date (July 14, 2026) or immediately prior to the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Sasser's continued service to Shattuck Labs, Inc.
• The options have an expiration date of July 14, 2035.
• Following this transaction, Ms. Sasser beneficially owns 33,150 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the stock option grant aligns the director's interests with shareholders and is a standard compensation practice, indicating stability in governance. It is not highly impactful on its own.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, aiding in retention of experienced board members.

Negatives

• The issuance of new options could lead to minor dilution for existing shareholders upon exercise, though this is a common aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Amy Kate Sasser are set to vest in full on the earlier of July 14, 2026, or immediately prior to the Issuer's next annual meeting of stockholders, subject to her continued service. This establishes a future milestone for the director's equity ownership.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This aligns with typical industry standards for attracting and retaining qualified board members by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are provided within this Form 4 filing to assess against global benchmarks. The document details a standard equity compensation grant to a director, which is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.

Related Party Transactions

• The grant of stock options to Amy Kate Sasser, a Director of Shattuck Labs, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from increased alignment of director's interests with long-term stock performance.
• Director (Amy Kate Sasser): Receives equity compensation, providing a direct financial incentive tied to the company's stock value and continued service.

Next Steps

• The stock options will vest in full on the earlier of July 14, 2026, or immediately prior to the Issuer's next annual meeting of stockholders, contingent on continued service.
• Following vesting, the director may choose to exercise the options at the specified exercise price before the expiration date of July 14, 2035.

Key Dates

Keywords

Shattuck Labs, STTK, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting